Cargando…

Microvascular invasion may be the determining factor in selecting TACE as the initial treatment in patients with hepatocellular carcinoma

The aim of this study was to investigate factors affecting tumor necrosis with transcatheter arterial chemoembolization (TACE). Factors associated with early hepatocellular carcinoma recurrence after curative hepatectomy were also evaluated. Data of 51 patients who underwent surgery after a single s...

Descripción completa

Detalles Bibliográficos
Autores principales: Jeong, Joonho, Park, Jung Gu, Seo, Kwang Ill, Ahn, Ji Hyun, Park, Jae Chun, Yun, Byung Cheol, Lee, Sang Uk, Lee, Jin Wook, Yun, Jong Hyouk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8270609/
https://www.ncbi.nlm.nih.gov/pubmed/34232206
http://dx.doi.org/10.1097/MD.0000000000026584
_version_ 1783720831746048000
author Jeong, Joonho
Park, Jung Gu
Seo, Kwang Ill
Ahn, Ji Hyun
Park, Jae Chun
Yun, Byung Cheol
Lee, Sang Uk
Lee, Jin Wook
Yun, Jong Hyouk
author_facet Jeong, Joonho
Park, Jung Gu
Seo, Kwang Ill
Ahn, Ji Hyun
Park, Jae Chun
Yun, Byung Cheol
Lee, Sang Uk
Lee, Jin Wook
Yun, Jong Hyouk
author_sort Jeong, Joonho
collection PubMed
description The aim of this study was to investigate factors affecting tumor necrosis with transcatheter arterial chemoembolization (TACE). Factors associated with early hepatocellular carcinoma recurrence after curative hepatectomy were also evaluated. Data of 51 patients who underwent surgery after a single session of TACE at a single university hospital were retrospectively analyzed. Factors that might affect tumor necrosis were determined by evaluating the TACE approach and by analyzing computed tomography and TACE findings, pathologic reports, and laboratory findings. In univariate analysis, microvascular invasion (MVI), radiological capsule appearance on the computed tomography, chronic hepatitis B, diabetes mellitus and serum albumin, MVI were significantly associated with tumor necrosis by TACE (P < .02). In multivariate analysis, MVI was the only statistically significant factor in TACE-induced tumor necrosis (P = .001). In univariate and multivariate analysis, MVI was the strongest factor for recurrence-free survival rate within 2 years (P = .008, P = .002). MVI could be a crucial factor in determining TACE as an initial treatment for hepatocellular carcinoma. MVI is also a strong indicator of recurrence within 2 years after curative hepatic resection.
format Online
Article
Text
id pubmed-8270609
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-82706092021-07-12 Microvascular invasion may be the determining factor in selecting TACE as the initial treatment in patients with hepatocellular carcinoma Jeong, Joonho Park, Jung Gu Seo, Kwang Ill Ahn, Ji Hyun Park, Jae Chun Yun, Byung Cheol Lee, Sang Uk Lee, Jin Wook Yun, Jong Hyouk Medicine (Baltimore) 4500 The aim of this study was to investigate factors affecting tumor necrosis with transcatheter arterial chemoembolization (TACE). Factors associated with early hepatocellular carcinoma recurrence after curative hepatectomy were also evaluated. Data of 51 patients who underwent surgery after a single session of TACE at a single university hospital were retrospectively analyzed. Factors that might affect tumor necrosis were determined by evaluating the TACE approach and by analyzing computed tomography and TACE findings, pathologic reports, and laboratory findings. In univariate analysis, microvascular invasion (MVI), radiological capsule appearance on the computed tomography, chronic hepatitis B, diabetes mellitus and serum albumin, MVI were significantly associated with tumor necrosis by TACE (P < .02). In multivariate analysis, MVI was the only statistically significant factor in TACE-induced tumor necrosis (P = .001). In univariate and multivariate analysis, MVI was the strongest factor for recurrence-free survival rate within 2 years (P = .008, P = .002). MVI could be a crucial factor in determining TACE as an initial treatment for hepatocellular carcinoma. MVI is also a strong indicator of recurrence within 2 years after curative hepatic resection. Lippincott Williams & Wilkins 2021-07-09 /pmc/articles/PMC8270609/ /pubmed/34232206 http://dx.doi.org/10.1097/MD.0000000000026584 Text en Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0 (https://creativecommons.org/licenses/by/4.0/)
spellingShingle 4500
Jeong, Joonho
Park, Jung Gu
Seo, Kwang Ill
Ahn, Ji Hyun
Park, Jae Chun
Yun, Byung Cheol
Lee, Sang Uk
Lee, Jin Wook
Yun, Jong Hyouk
Microvascular invasion may be the determining factor in selecting TACE as the initial treatment in patients with hepatocellular carcinoma
title Microvascular invasion may be the determining factor in selecting TACE as the initial treatment in patients with hepatocellular carcinoma
title_full Microvascular invasion may be the determining factor in selecting TACE as the initial treatment in patients with hepatocellular carcinoma
title_fullStr Microvascular invasion may be the determining factor in selecting TACE as the initial treatment in patients with hepatocellular carcinoma
title_full_unstemmed Microvascular invasion may be the determining factor in selecting TACE as the initial treatment in patients with hepatocellular carcinoma
title_short Microvascular invasion may be the determining factor in selecting TACE as the initial treatment in patients with hepatocellular carcinoma
title_sort microvascular invasion may be the determining factor in selecting tace as the initial treatment in patients with hepatocellular carcinoma
topic 4500
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8270609/
https://www.ncbi.nlm.nih.gov/pubmed/34232206
http://dx.doi.org/10.1097/MD.0000000000026584
work_keys_str_mv AT jeongjoonho microvascularinvasionmaybethedeterminingfactorinselectingtaceastheinitialtreatmentinpatientswithhepatocellularcarcinoma
AT parkjunggu microvascularinvasionmaybethedeterminingfactorinselectingtaceastheinitialtreatmentinpatientswithhepatocellularcarcinoma
AT seokwangill microvascularinvasionmaybethedeterminingfactorinselectingtaceastheinitialtreatmentinpatientswithhepatocellularcarcinoma
AT ahnjihyun microvascularinvasionmaybethedeterminingfactorinselectingtaceastheinitialtreatmentinpatientswithhepatocellularcarcinoma
AT parkjaechun microvascularinvasionmaybethedeterminingfactorinselectingtaceastheinitialtreatmentinpatientswithhepatocellularcarcinoma
AT yunbyungcheol microvascularinvasionmaybethedeterminingfactorinselectingtaceastheinitialtreatmentinpatientswithhepatocellularcarcinoma
AT leesanguk microvascularinvasionmaybethedeterminingfactorinselectingtaceastheinitialtreatmentinpatientswithhepatocellularcarcinoma
AT leejinwook microvascularinvasionmaybethedeterminingfactorinselectingtaceastheinitialtreatmentinpatientswithhepatocellularcarcinoma
AT yunjonghyouk microvascularinvasionmaybethedeterminingfactorinselectingtaceastheinitialtreatmentinpatientswithhepatocellularcarcinoma